<DOC>
	<DOCNO>NCT02524197</DOCNO>
	<brief_summary>To assess safety tolerability orally-administered CR845 patient osteoarthritis ( OA ) hip knee . The study drug test reduce OA pain , take twice day two week , four different dos ( strength ) test . From screen period follow examination , study expect last 38 day per participant .</brief_summary>
	<brief_title>A Study Safety Effectiveness Orally Administered CR845 Patients With Osteoarthritis Hip Knee</brief_title>
	<detailed_description>The purpose clinical study collect information effectiveness CR845 look safety different dose level CR845 tablet . Oral CR845 test healthy people . This first time oral CR845 test patient osteoarthritis . Four different dos CR845 test study . Participants assign one four treatment group . The first 6 participant 4 treatment group give study drug inpatient study unit ( clinic ) approximately 2 day . Frequent blood sample take measure drug level 2 day . Also , study drug ( CR845 ) know increase urination first day , amount fluid participant drink amount urine void first day also measure . At end second day , member clinical staff check vital sign patient 's laboratory result prior discharge clinic . After , remainder treatment period outpatient ( home ) . This involve take additional two tablet twice day , maintain diary return clinic upon completion .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<criteria>A patient eligible enrollment follow criterion meet : 1 . Voluntarily provide write informed consent participate study prior study procedure . 2 . Is able speak , read , communicate clearly English Spanish ; able understand study procedure . 3 . Male female ≥ 25 year age . 4 . BMI ≤ 40 5 . Has OA hip knee accord American College Rheumatology ( ACR ) criterion . 6 . Reports average pain intensity level ≥ 4 index joint Screening NRS . 7 . Willing discontinue currently use pain medication begin 5 day prior Baseline Visit throughout study . 8 . If female : 1 . Of childbearing potential patient must willing practice acceptable form birth control ( define use intrauterine device ; barrier method spermicide ; condom , form hormonal contraceptive ; abstinence sexual intercourse ) duration treatment least 3 day follow last dose study drug . 2 . Of nonchildbearing potential patient must surgically biologically sterile ( hysterectomy , bilateral oophorectomy , bilateral tubal ligation , postmenopausal least 1 year ) . 9 . If male , patient must surgically biologically sterile . If sterile , patient must agree use acceptable form birth control heterosexual partner ( describe inclusion criterion # 8 ) abstain sexual relation treatment period 3 day follow last dose study drug . 10 . Is free physical , mental , medical condition , , opinion Investigator , would make study participation inadvisable . 11 . Reports average daily pain intensity ≥ 4 index joint 3 day prior Baseline NRS . A patient exclude enrollment patient meet follow criterion : 1 . Has joint replacement index joint . 2 . Has receive intraarticular injection corticosteroid hyaluronic acid index joint within 3 month prior Screening Visit . 3 . Has start new medication chronic illness within 30 day prior Screening Visit . 4 . Has history current diagnosis substance dependence ( except caffeine nicotine ) alcohol abuse , accord criterion Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM5 ) . 5 . Has positive urine drug screen drug abuse Screening Baseline . 6 . Has diagnose condition hyperhidrosis primary hypodipsia . 7 . Has history ( within 6 month ) clinically meaningful orthostatic change vital sign , OR , Screening , decrease systolic blood pressure &gt; 20 mm Hg decrease diastolic blood pressure 10 mm Hg together increase heart rate &gt; 30 beat per minute transition supine standing measurement . 8 . Has medical condition ( e.g. , cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine [ adrenal hyperplasia ] , immunologic , dermatologic , neurologic , oncologic , psychiatric condition ) significant laboratory abnormality , Investigator 's opinion , would jeopardize safety patient likely confound study measurement . 9 . Has serum sodium level &gt; 145 mmol/L Screening . 10 . Has impair renal function indicate serum creatinine &gt; 2 × reference upper limit normal ( ULN ) . 11 . Has serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 × reference ULN , total bilirubin &gt; 2 × ULN Screening . 12 . Has , opinion Investigator , clinical sign dehydration hypovolemia ( e.g. , symptomatic hypotension ) associate laboratory abnormality ( e.g. , elevate hematocrit elevate blood urea nitrogen [ BUN ] &gt; 1.5 × reference ULN ) Screening . 13 . Has take opioid nonopioid pain medication ( e.g. , nonsteroidal antiinflammatory drug [ NSAIDs ] naproxen cyclooxygenase2 inhibitor ) within 5 day prior study drug administration . 14 . Has receive another investigational drug within 30 day prior Baseline plan participate another clinical trial enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hip</keyword>
	<keyword>Knee</keyword>
	<keyword>Arthritis</keyword>
	<keyword>pain</keyword>
	<keyword>CR845</keyword>
	<keyword>kappa opioid</keyword>
</DOC>